Stada Grabs GSK Brands In EU
German Generics Giant Becomes Major Consumer Healthcare Player
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.
You may also be interested in...
Stada has expanded its business with another acquisition in the consumer healthcare space, this time striking a deal with Sanofi for 16 brands across 13 European markets.
Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.